latest news releases from the newsroom
NetCom Lowers Prices for Pre-Paid SMS
STOCKHOLM, Sweden, March 3, 2004 (PRIMEZONE) -- TeliaSonera's subsidiary NetCom is reducing the price on pre-paid SMS an additional 0.10 NOK to 0.69 NOK per SMS. This means that all NetCom SMS users will now pay 0.69 NOK per message.
Basilea Pharmaceutica Ltd
Positive Phase II Results for Basilea's Novel First-In-Class Antibiotic
BASEL, Switzerland, March 3, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG today announced positive phase II results for BAL5788 in the indication of complicated skin and skin structure infections (cSSSI). BAL5788 is the first of a new class of broad-spectrum cephalosporin antibiotics also active against multi-resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). In March 2003 the FDA awarded BAL5788 Fast Track review status in recognition of its therapeutic potential to treat severe infections.
Ahold Divests Thai Operation, Withdrawal from Asia Completed
ZAANDAM, The Netherlands, March 03, 2004 (PRIMEZONE) -- Ahold today announced it has reached agreement on the sale of its stake in CRC.Ahold, operating in Thailand, to its partner, the Central Group. The divestment, which is effective immediately, is the final step in the overall sale of Ahold's Asian operations. The transaction sum was not disclosed.
Novartis Ophthalmics, Inc.
Flemming Ornskov, MD, President, Novartis Ophthalmics, To Receive Distinguished Corporate Achievement Award at Winternight 2004, a Gala Benefit for Lighthouse International
NEW YORK, March 2, 2004 (PRIMEZONE) -- Flemming Ornskov, MD, President of Novartis Ophthalmics, will receive a Distinguished Corporate Achievement Award, at Winternight 2004, a Gala Benefit for Lighthouse International. Dr. Ornskov will accept the award, on behalf of the entire Novartis team, for its work to make Visudyne(r) (verteporfin for injection, 15mg), a drug for treating the severest form of macular degeneration, the breakthrough success it is.